SCHEDULE 13G/A: BlackRock Amends Passive Stake in Day One Biopharmaceuticals to 4.7%

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.7% passive beneficial ownership stake in Day One Biopharmaceuticals, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in Day One Biopharmaceuticals, Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 4,812,307 shares of Common Stock, representing 4.7% of the class.
• BlackRock, Inc. holds sole voting power over 4,750,931 shares and sole dispositive power over 4,812,307 shares, with no shared voting or dispositive power.
• The filing indicates that the securities are held in the ordinary course of business and not for the purpose of changing or influencing the control of Day One Biopharmaceuticals, Inc.
• One of BlackRock's subsidiaries, BlackRock Investment Management, LLC, is noted to beneficially own 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of passive ownership, providing neutral information without expressing positive or negative sentiment regarding the issuer's performance or outlook.

Risks

• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating control-related risks from this specific holding.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, BlackRock, regarding its passive investment in a biopharmaceutical company. Such filings are common and indicate ongoing portfolio management activities within the investment management industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, indicating BlackRock's continued, albeit slightly reduced, passive investment in the company. The fact that the aggregate holding is below 5% for BlackRock, Inc. but a subsidiary still holds above 5% provides nuanced insight into the institutional ownership structure.

Key Dates

Keywords

BlackRock, Day One Biopharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biopharmaceuticals